About this Series

Advanced lung cancer is always a difficult diagnosis for both patients and physicians, but immunotherapies are providing new hope for treating this disease. For a subset of patients, new immunotherapies are leading to sustained, durable responses that were previously unheard of in metastatic patients. But for every advance, new questions arise: How should approved agents be used? Is PD-L1 expression a reliable biomarker? What are the most common immune-related adverse events? Thoracic oncology leaders from NewYork-Presbyterian/Columbia University Medical Center and Seattle's Swedish Cancer Institute provide guidance on how to navigate this new treatment landscape.

Show More

Who's Who
More on Lung Cancer